The pace of prostate growth in a majority of men of northern European descent is as steady as a ticking clock and gives clinicians the opportunity to forecast prostate size in many patients with a single ultrasound measurement.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
2 Clarke Drive
Cranbury, NJ 08512